Rapid ART Initiation with BIC/FTC/TAF in People Who Inject Drugs in Greece: Results from a Pilot Single-Arm Study of an Integrated Care Model
Authors:
- Sotirios RoussosSotirios Roussos
- Konstantinos ProtopapasKonstantinos Protopapas
- Elpida MastrogianniEMElpida Mastrogianni
- Charisis TotsikasCTCharisis Totsikas
- Charalampos D. MoschopoulosCharalampos D. Moschopoulos
- Stylianos BourmpoutelisSBStylianos Bourmpoutelis
- Panagiota RestaPRPanagiota Resta
- Kassandra ProcterKPKassandra Procter
- Evangelos KokolesisEKEvangelos Kokolesis
- Anastasia AntoniadouAAAnastasia Antoniadou
- Antonios PapadopoulosAPAntonios Papadopoulos
- Vasileios PapastamopoulosVPVasileios Papastamopoulos
Open Access
- 26 November 2025
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2697
Abstract
People who inject drugs (PWIDs) remain underserved in HIV care. Evidence on rapid antiretroviral therapy (ART) for PWID is limited. We evaluated feasibility, effectiveness, safety, and patient-reported outcomes (PROs) for rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) supported by a peer navigation in Greece. This is a single-arm, multicenter pilot study including PWIDs (≥18 years) newly diagnosed or relinking after >3 months off ART. Participants started BIC/FTC/TAF on the same day or within 7 days and received peer navigation for 48 weeks. Co-primary endpoints were Week-24 virologic suppression (HIV-1 RNA < 50 copies/mL; FDA Snapshot) and grade 3–4 adverse events (AEs). Secondary endpoints included complete-case suppression at Weeks 24/48, CD4 recovery, retention, and PROs. Outcomes were compared with historical controls from the same centers. Thirty-seven participants were enrolled (83.8% male; median age 33.3 years). Median time to ART was 0 days (vs 78 in controls, p < 0.001). Retention was 67.6% at Week 24 and 54.1% at Week 48. In the primary (FDA Snapshot) analysis, suppression was 62.2% and 54.1% at Weeks 24 and 48; in complete-case analyses, results were 92.0% and 100%, respectively. Mean CD4 count increased by 208 cells/μL (95% CI 141–275) at Week 48. Quality of life improved and symptom burden decreased. No grade 3–4 AEs occurred. Rapid BIC/FTC/TAF with peer navigation eliminated delays to ART and achieved favorable virologic, immunologic, and PROs among those retained, with good tolerability. Despite retention challenges, this model appears feasible for PWID and may help close HIV care gaps toward UNAIDS 95–95–95 targets.Keywords
Funding Information
- Gilead (Not available now)
This publication has 12 references indexed in Scilit:
- Statistical models2025
- A new outbreak of HIV infection among people who inject drugs during the COVID-19 pandemic in GreeceInternational Journal of Drug Policy, 2023
- HIV treatment, antiretroviral adherence and AIDS mortality in people who inject drugs: a scoping reviewEuropean Journal of Public Health, 2023
- Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055Journal of Antimicrobial Chemotherapy, 2023
- Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?Clinical Infectious Diseases, 2020
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND StudyClinical Infectious Diseases, 2019
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 InfectionDrugs, 2018
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialThe Lancet, 2017
- Adherence to Antiretroviral Medications Among Persons Who Inject Drugs in Transitional, Low and Middle Income Countries: An International Systematic ReviewAIDS and Behavior, 2014
- Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year reviewHealth and Quality of Life Outcomes, 2013